Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence

Stefanie R. Bailey (), Michelle H. Nelson, Kinga Majchrzak, Jacob S. Bowers, Megan M. Wyatt, Aubrey S. Smith, Lillian R. Neal, Keisuke Shirai, Carmine Carpenito, Carl H. June, Michael J. Zilliox and Chrystal M. Paulos ()
Additional contact information
Stefanie R. Bailey: Medical University of South Carolina
Michelle H. Nelson: Medical University of South Carolina
Kinga Majchrzak: Medical University of South Carolina
Jacob S. Bowers: Medical University of South Carolina
Megan M. Wyatt: Medical University of South Carolina
Aubrey S. Smith: Medical University of South Carolina
Lillian R. Neal: Medical University of South Carolina
Keisuke Shirai: Hollings Cancer Center, Medical University of South Carolina
Carmine Carpenito: University of Pennsylvania Cancer Center
Carl H. June: University of Pennsylvania Cancer Center
Michael J. Zilliox: Stritch School of Medicine, Loyola University Chicago
Chrystal M. Paulos: Medical University of South Carolina

Nature Communications, 2017, vol. 8, issue 1, 1-13

Abstract: Abstract CD8+ T lymphocytes mediate potent immune responses against tumor, but the role of human CD4+ T cell subsets in cancer immunotherapy remains ill-defined. Herein, we exhibit that CD26 identifies three T helper subsets with distinct immunological properties in both healthy individuals and cancer patients. Although CD26neg T cells possess a regulatory phenotype, CD26int T cells are mainly naive and CD26high T cells appear terminally differentiated and exhausted. Paradoxically, CD26high T cells persist in and regress multiple solid tumors following adoptive cell transfer. Further analysis revealed that CD26high cells have a rich chemokine receptor profile (including CCR2 and CCR5), profound cytotoxicity (Granzyme B and CD107A), resistance to apoptosis (c-KIT and Bcl2), and enhanced stemness (β-catenin and Lef1). These properties license CD26high T cells with a natural capacity to traffic to, regress and survive in solid tumors. Collectively, these findings identify CD4+ T cell subsets with properties critical for improving cancer immunotherapy.

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-017-01867-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-01867-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-017-01867-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().